摘要
目的:分析不同周期AT化疗方案治疗改良根治术后三阴性乳腺癌(TNBC)患者的效果。方法:回顾性分析2018年1-12月在沧州市中心医院就诊的46例乳腺癌患者的临床资料,根据化疗周期差异分为观察组和对照组,每组23例。观察组改良根治术后予以连续6个疗程的AT方案;对照组术后予以连续4个疗程的AT方案。比较两组疗效、化疗期间不良反应的发生情况及肿瘤标记物的浓度水平。结果:化疗后,观察组1年客观缓解率(ORR)、2年无病生存率(DFS)与总生存率(OS)均高于对照组,差异均有统计学意义(P<0.05)。两组1年内DFS与OS比较,差异均无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组Ki-67、糖类抗原153(CA-153)、癌胚抗原(CEA)水平比较,差异均无统计学意义(P>0.05);治疗后,观察组CEA、Ki-67、CA-153水平均低于对照组,差异均有统计学意义(P<0.05)。结论:相比4个周期化疗,术后予6个周期化疗的TNBC患者的临床疗效更佳、肿瘤标记物水平降幅更为显著。此外,适当延长化疗周期,并不会明显增加不良反应的发生率,患者耐受性较好。
Objective:To analyze the clinical efficacy of different cycles of AT chemotherapy in the treatment of patients with triple-negative breast cancer(TNBC)after modified radical resection.Method:The clinical data of 46 patients with breast cancer treated in Cangzhou Central Hospital from January 2018 to December 2018 were retrospectively analyzed,according to the difference of chemotherapy cycles,they were divided into observation group and control group,with 23 cases in each group.Observation group was given AT regimen for 6 consecutive courses after modified radical resection,control group was given AT regimen for 4 consecutive courses after surgery.The efficacy,adverse reactions during chemotherapy and the concentration of tumor markers were compared between the two groups.Result:After chemotherapy,the 1 year objective response rate(ORR),2 years disease-free survival rate(DFS)and overall survival rate(OS)of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in DFS and OS between two groups within 1 year(P>0.05).There was no significant difference in the occurrence of adverse reactions between two groups(P>0.05).Before treatment,there were no significant differences in the levels of Ki-67,carbohydrate antigen 153(CA-153)and carcinoembryonic antigen(CEA)between two groups(P>0.05);after treatment,the levels of CEA,Ki-67 and CA-153 of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:Compared with 4 cycles of chemotherapy,patients with TNBC who received 6 cycles of postoperative chemotherapy have better clinical efficacy and more significant decrease in tumor marker levels.In addition,appropriately prolonging the chemotherapy cycle will not significantly increase the incidence of adverse reactions,and the patient’s tolerance is good.
作者
张恒乐
张嘉澍
张晓宇
ZHANG Hengle;ZHANG Jiashu;ZHANG Xiaoyu(Hebei Medical University,Shijiazhuang 050017,China;不详)
出处
《中国医学创新》
CAS
2022年第20期59-63,共5页
Medical Innovation of China
关键词
辅助化疗
化疗周期
三阴性乳腺癌
Adjuvant chemotherapy
Chemotherapy cycle
Triple negative breast cancer
